tiprankstipranks
AIM ImmunoTech completes cGMP manufacturing of clinical vials of Ampligen
PremiumThe FlyAIM ImmunoTech completes cGMP manufacturing of clinical vials of Ampligen
10d ago
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
PremiumPress Releases
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
17d ago
AIM ImmunoTech announces evaluation of first dose level in Phase 1b/2 study
PremiumThe Fly
AIM ImmunoTech announces evaluation of first dose level in Phase 1b/2 study
17d ago
AIM ImmunoTech appoints Lapp as a consulting Medical Officer
PremiumThe FlyAIM ImmunoTech appoints Lapp as a consulting Medical Officer
1M ago
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
PremiumPress Releases
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
1M ago
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
PremiumPress Releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
1M ago
AIM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsAIM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
PremiumPress Releases
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
2M ago
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
PremiumPress Releases
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100